ImmuneOncia

ImmuneOncia Therapeutics, Inc. is an immuno-oncology-focused biopharmaceutical company that develops drugs for the treatment of cancer. Its pipeline includes IMC-001, an IgG1 human monoclonal antibody targeting PD-L1 that is in Phase II trials for NK/T cell lymphoma and solid cancers with high tumor mutation burden, and IMC-002, an IgG4 human monoclonal antibody targeting CD47 that is in Phase I trials for solid cancers such as triple-negative breast cancer, hepatocellular carcinoma, and bile duct cancer. The company is also developing preclinical candidates: IMC-201, a CD47xPD-L1 dual antibody immunotherapy, and IMC-202, a PD-L1xTIGIT dual antibody immunotherapy. Incorporated in 2016 and headquartered in Yongin-si, South Korea, it operates as a subsidiary of Yuhan Corporation.